Ahmed A. Ezat
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ahmed A. Ezat has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Medhat Ibrahim
Spectroscopy Department, National Research Centre, Giza, Egypt
2 shared publications - Abdo A. Elfiky
Biophysics Department, Faculty of Science, Cairo University, Giza, Egypt
1 shared publication - Abeer Mousa Alkhaibari
Department of Biology, Faculty of Science, University of Tabuk, Tabuk 71491, Saudi Arabia
1 shared publication - Amr Mohamed
Department of Entomology, Faculty of Science, Cairo University, Giza 12613, Egypt
1 shared publication Hamdy I. A. Mostafa
Biophysics Department, Faculty of Science, University of Cairo, Giza, Egypt
1 shared publicationHamdyI. Mostafa
1 shared publication
Latest Publications
- Open Access
Ligand-Specific Remodeling of the Anopheles gambiae RDL GABA Receptor by the A296S Mutation Differentiates Recognition of Fipronil and Fluralaner
The γ-aminobutyric acid (GABA)-gated chloride channel Resistance to Dieldrin (RDL) receptor is a major molecular target of insecticides, yet the structural basis by which resistance-associated mutations differentially influence chemically distinct ligands remains incompletely understood. Here, we investigated the effects of the classical A296S substitution on the interactions of the Anopheles gambiae RDL receptor with the phenylpyrazole fipronil and the isoxazoline fluralaner using homology modeling, molecular docking, 200 ns molecular dynamics simulations (apo receptors and three independent replicas of each ligand-bound complex), and MM/PBSA free-energy calculations that include an interaction-entropy (IE) term. Apo-state molecular dynamics simulations showed that A296S preserved the overall structural stability of the receptor while locally modifying the environment of the pore-lining M2 transmembrane helix. Although docking scored fluralaner more favorably than fipronil in both receptor variants, the replicated molecular dynamics simulations revealed ligand- and genotype-dependent behavior. In the wild-type receptor, fluralaner remained stably bound and had a favorable MM/PBSA free-energy estimate (−18.3 ± 4.2 kcal/mol), whereas the ligand RMSD of fipronil increased progressively and its estimate was close to zero (+1.2 ± 9.5 kcal/mol). In the A296S model, the fipronil estimate was similar (+1.6 ± 4.3 kcal/mol), but the fluralaner estimate became unfavorable (+10.0 ± 1.8 kcal/mol), and Ser296 itself contributed slightly unfavorably to both ligands. Together, these findings indicate that A296S does not act as a universal determinant of ligand recognition but is associated with ligand-specific changes in the modeled interaction landscape, with the larger predicted effect on fluralaner. These predictions derive from a homology model, were not tested by electrophysiology or binding assays, and do not measure functional resistance. They may nonetheless help inform the interpretation of cross-resistance patterns and structure-guided efforts targeting GABA receptor-based insecticides.
Open AccessLigand-Specific Remodeling of the Anopheles gambiae RDL GABA Receptor by the A296S Mutation Differentiates Recognition of Fipronil and Fluralaner
The γ-aminobutyric acid (GABA)-gated chloride channel Resistance to Dieldrin (RDL) receptor is a major molecular target of insecticides, yet the structural basis by which resistance-associated mutations differentially influence chemically distinct ligands remains incompletely understood. Here, we investigated the effects of the classical A296S substitution on the interactions of the Anopheles gambiae RDL receptor with the phenylpyrazole fipronil and the isoxazoline fluralaner using homology modeling, molecular docking, 200 ns molecular dynamics simulations (apo receptors and three independent replicas of each ligand-bound complex), and MM/PBSA free-energy calculations that include an interaction-entropy (IE) term. Apo-state molecular dynamics simulations showed that A296S preserved the overall structural stability of the receptor while locally modifying the environment of the pore-lining M2 transmembrane helix. Although docking scored fluralaner more favorably than fipronil in both receptor variants, the replicated molecular dynamics simulations revealed ligand- and genotype-dependent behavior. In the wild-type receptor, fluralaner remained stably bound and had a favorable MM/PBSA free-energy estimate (−18.3 ± 4.2 kcal/mol), whereas the ligand RMSD of fipronil increased progressively and its estimate was close to zero (+1.2 ± 9.5 kcal/mol). In the A296S model, the fipronil estimate was similar (+1.6 ± 4.3 kcal/mol), but the fluralaner estimate became unfavorable (+10.0 ± 1.8 kcal/mol), and Ser296 itself contributed slightly unfavorably to both ligands. Together, these findings indicate that A296S does not act as a universal determinant of ligand recognition but is associated with ligand-specific changes in the modeled interaction landscape, with the larger predicted effect on fluralaner. These predictions derive from a homology model, were not tested by electrophysiology or binding assays, and do not measure functional resistance. They may nonetheless help inform the interpretation of cross-resistance patterns and structure-guided efforts targeting GABA receptor-based insecticides.
- 1 January 2019
- Published by Elsevier in Life Sciences
- Vol. 217, 176-184
A comparative study of the efficiency of HCV NS3/4A protease drugs against different HCV genotypes using in silico approaches
- 1 January 2019
- Published by Elsevier in Life Sciences
- Vol. 217, 176-184
A comparative study of the efficiency of HCV NS3/4A protease drugs against different HCV genotypes using in silico approaches
- 1 January 2015
- Published by American Scientific Publishers in Journal of Computational and Theoretical Nanoscience
- Vol. 12 (1) , 52-59
Computational Approaches to Study Peptidomimetic and Macrocyclic Hepatitis C Virus NS3 Protease Inhibitors
- 1 January 2015
- Published by American Scientific Publishers in Journal of Computational and Theoretical Nanoscience
- Vol. 12 (1) , 52-59
Computational Approaches to Study Peptidomimetic and Macrocyclic Hepatitis C Virus NS3 Protease Inhibitors
- 28 December 2013
- Published by Springer Nature in The Protein Journal
- Vol. 33 (1) , 32-47
Molecular Docking Investigation of the Binding Interactions of Macrocyclic Inhibitors with HCV NS3 Protease and its Mutants (R155K, D168A and A156V)
Hepatitis C Virus (HCV) non-structural protein 3 (NS3) protease drug resistance poses serious challenges on the design of an effective treatment. Substrate Envelope Hypothesis, “the substrates of HCV NS3/4A protease have a consensus volume inside the active site called substrate envelope” is used to design potent and specific drugs to overcome this problem. Using molecular docking, we studied the binding interaction of the different inhibitors and protein and evaluated the effect of three different mutations (R155K, D168A and A156V) on the binding of inhibitors. P2–P4 macrocycles of 5A/5B and modified 5A/5B hexapeptide sequences have the best scores against the wild-type protein −204.506 and −206.823 kcal/mole, respectively. Also, charged P2–P4 macrocycles of 3/4A and 4A/4B hexapeptide sequences have low scores with the wild-type protein −200.467 and −203.186 kcal/mole, respectively. R155K mutation greatly affects the conformation of the compounds inside the active site. It inverts its orientations, and this is because the large and free side chain of K155 which restricts the conformation of the large P2–P4 macrocycle. The conformation of charged P2–P4 macrocycle of 3/4A hexapeptide sequence in wild-type, A156V and D168A proteins is nearly equal; while that of charged P2–P4 macrocycle of 4A/4B hexapeptide sequence is different. Nevertheless, these compounds have a slight increase of Van der Waals volume compared to that of substrates, they are potent against mutations and have good scores. Therefore, the suggested drugs can be used as an effective treatment solving HCV NS3/4A protease drug resistance problem.
- 28 December 2013
- Published by Springer Nature in The Protein Journal
- Vol. 33 (1) , 32-47
Molecular Docking Investigation of the Binding Interactions of Macrocyclic Inhibitors with HCV NS3 Protease and its Mutants (R155K, D168A and A156V)
Hepatitis C Virus (HCV) non-structural protein 3 (NS3) protease drug resistance poses serious challenges on the design of an effective treatment. Substrate Envelope Hypothesis, “the substrates of HCV NS3/4A protease have a consensus volume inside the active site called substrate envelope” is used to design potent and specific drugs to overcome this problem. Using molecular docking, we studied the binding interaction of the different inhibitors and protein and evaluated the effect of three different mutations (R155K, D168A and A156V) on the binding of inhibitors. P2–P4 macrocycles of 5A/5B and modified 5A/5B hexapeptide sequences have the best scores against the wild-type protein −204.506 and −206.823 kcal/mole, respectively. Also, charged P2–P4 macrocycles of 3/4A and 4A/4B hexapeptide sequences have low scores with the wild-type protein −200.467 and −203.186 kcal/mole, respectively. R155K mutation greatly affects the conformation of the compounds inside the active site. It inverts its orientations, and this is because the large and free side chain of K155 which restricts the conformation of the large P2–P4 macrocycle. The conformation of charged P2–P4 macrocycle of 3/4A hexapeptide sequence in wild-type, A156V and D168A proteins is nearly equal; while that of charged P2–P4 macrocycle of 4A/4B hexapeptide sequence is different. Nevertheless, these compounds have a slight increase of Van der Waals volume compared to that of substrates, they are potent against mutations and have good scores. Therefore, the suggested drugs can be used as an effective treatment solving HCV NS3/4A protease drug resistance problem.